title: Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy.
abstract: BACKGROUND
  In cases of myeloma cast nephropathy in need of haemodialysis (HD), reduction of free light chains using HD with High-Cut-Off filters (HCO-HD), in combination with chemotherapy, may be associated with better renal recovery. The aim of the present study is to evaluate the effectiveness of haemodiafiltration (HDF) in reducing free light chain levels using a less expensive heat sterilized high-flux polyphenylene HF dialyzer (HF-HDF).
  
  
  METHODS
  In a single-centre prospective cohort study, 327 dialysis sessions were performed using a 2.2 m2 heat sterilized high-flux polyphenylene HF dialyzer (Phylther HF22SD), a small (1.1m2) or large (2.1 m2) high-cut-off (HCO) dialyzer (HCOS and HCOL) in a cohort of 16 patients presenting with dialysis-dependent acute cast nephropathy and elevated free light chains (10 kappa, 6 lambda). The outcomes of the study were the mean reduction ratio (RR) of kappa and lambda, the proportion of treatments with an RR of at least 0.65, albumin loss and the description of patient outcomes. Statistical analysis was performed using linear and logistic regression through generalized estimating equation analysis so as to take into account repeated observation within subjects and adjust for session duration.
  
  
  RESULTS
  There were no significant differences in the estimated marginal mean of kappa RR, which were respectively 0.67, 0.69 and 0.70 with HCOL-HD, HCOS-HDF and HF-HDF (P = 0.950). The estimated marginal mean of the proportions of treatments with a kappa RR ≥0.65 were 68%, 63% and 71% with HCOL-HD, HCOS-HDF and HF-HDF, respectively (P = 0.913). The estimated marginal mean of lambda RR were higher with HCOL-HDF (0.78), compared to HCOL-HD and HF-HDF (0.62, and 0.61 respectively). The estimated marginal mean proportion of treatments with a lambda RR ≥0.65 were higher with HCOL-HDF (81%), compared to 57% in HF-HDF (P = 0.042). The median albumin loss were 7, 21 and 63 g/session with HF-HDF, HCOL-HD and HCOL-HDF respectively (P = 0.044). Among survivors, 9 out of 10 episodes of acute kidney injuries became dialysis-independent following a median time of renal replacement therapy of 40 days (range 7-181).
  
  
  CONCLUSIONS
  Therefore, in patients with acute dialysis-dependent myeloma cast nephropathy, in addition to chemotherapy, HDF with a heat sterilized high-flux polyphenylene HF dialyzer could offer an alternative to HCO dialysis for extracorporeal kappa reduction with lower albumin loss.
authors.affiliation: Division of Nephrology, Department of Medicine, CHU de Quebec-Hôtel-Dieu de Québec, Quebec, Canada; Department of Medicine, Faculty of Medicine, Université Laval, Québec, Québec, Canada.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Rousseau-Gagnon
authors.affiliation: Division of Nephrology, Department of Medicine, CHU de Quebec-Hôtel-Dieu de Québec, Quebec, Canada; Department of Medicine, Faculty of Medicine, Université Laval, Québec, Québec, Canada.
authors.forename: Mohsen
authors.initials: M
authors.lastname: Agharazii
authors.affiliation: Division of Nephrology, Department of Medicine, CHU de Quebec-Hôtel-Dieu de Québec, Quebec, Canada; Department of Medicine, Faculty of Medicine, Université Laval, Québec, Québec, Canada.
authors.forename: Sacha A
authors.initials: SA
authors.lastname: De Serres
authors.affiliation: Division of Nephrology, Department of Medicine, CHU de Quebec-Hôtel-Dieu de Québec, Quebec, Canada; Department of Medicine, Faculty of Medicine, Université Laval, Québec, Québec, Canada.
authors.forename: Simon
authors.initials: S
authors.lastname: Desmeules
mesh_terms: D058186:Acute Kidney Injury / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality / Q000628:therapy*; D000368:Aged; D015415:Biomarkers; D015314:Dialysis Solutions; D005260:Female; D017583:Hemodiafiltration / Q000379:methods; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000009:adverse effects* / Q000097:blood; D007145:Immunoglobulin kappa-Chains / Q000009:adverse effects / Q000097:blood; D007146:Immunoglobulin lambda-Chains / Q000009:adverse effects / Q000097:blood; D007677:Kidney Function Tests; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications*; D011108:Polymers; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D015314:Dialysis Solutions; D007147:Immunoglobulin Light Chains; D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D011108:Polymers; C041325:polyphenylene sulfide